VAS2870 effectively inhibits PDGF-BB-induced activation of NADPH oxidase and the resulting increase in intracellular ROS production. Additionally, VAS2870 blocks PDGF-BB-stimulated chemotaxis without affecting DNA synthesis. Preincubation with VAS2870 (10 and 20 µM) entirely prevents PDGF-triggered NADPH oxidase activation and ROS generation. However, preincubation with VAS2870 across a range of concentrations (0.1-20 µM) does not impact PDGF-driven cell cycle progression. Still, it completely inhibits PDGF-dependent chemotaxis of VSMCs in a concentration-dependent manner, achieving 100% inhibition at 10 µM^[1].

VAS2870 dose-dependently suppresses autocrine-induced proliferation in FaO rat hepatoma cells and nearly eliminates ROS production and thymidine incorporation at 25 mM. It also inhibits serum-stimulated growth of FaO rat hepatoma cells. Furthermore, VAS2870 reduces the proliferation of various human hepatocellular carcinoma (HCC) cell lines. Pretreatment with VAS2870 augments TGF-β-induced apoptosis in FaO rat hepatoma cells^[2].